Dataset Information


Aidi injection, a traditional Chinese biomedical preparation for gynecologic tumors: a systematic review and PRISMA-compliant meta-analysis.

ABSTRACT: Aidi injection (ADI), a traditional Chinese biomedical preparation, is a promising adjuvant therapy for gynecologic tumors (GTs), including cervical cancer (CC), endometrial cancer (EC), and ovarian cancer (OC). Although studies have reported positively on ADI therapy, its exact effects and safety in GT patients remain controversial. Therefore, a wide-ranging systematic search of electronic databases was performed for this meta-analysis. Data from 38 trials including 3309 GT patients were analyzed. The results indicated that the combination of conventional treatment and ADI markedly improved the patients' overall response rate (P<0.00001), disease control rate (P<0.00001), and quality of life (P<0.05) compared with conventional treatment alone. Furthermore, patient immunity was enhanced with combined treatment, as indicated by significantly increased percentages of CD3+ (P=0.005) and CD4+ (P<0.00001) and increased CD4+/CD8+ ratio (P=0.001). Most of the adverse events caused by radiochemotherapy such as gastrointestinal issues, leukopenia, thrombocytopenia, and hepatotoxicity, (P<0.05 for all) were significantly alleviated when ADI was used in the GT patients. However, other adverse events such as nephrotoxicity, diarrhea, alopecia, and neurotoxicity did not significantly differ between the two groups. Overall, these results suggest that the combination of conventional and ADI treatment is more effective than conventional treatment alone.


PROVIDER: S-EPMC7937908 | BioStudies | 2021-01-01

REPOSITORIES: biostudies

Similar Datasets

2020-01-01 | S-EPMC7441486 | BioStudies
2020-01-01 | S-EPMC7069918 | BioStudies
2020-01-01 | S-EPMC6970085 | BioStudies
1000-01-01 | S-EPMC5008545 | BioStudies
2019-01-01 | S-EPMC6881210 | BioStudies
2020-01-01 | S-EPMC7422476 | BioStudies
2019-01-01 | S-EPMC6605674 | BioStudies
2017-01-01 | S-EPMC5574601 | BioStudies
2020-01-01 | S-EPMC7642815 | BioStudies
1000-01-01 | S-EPMC5319511 | BioStudies